Evidence map›Paper›PMID 29859176›Full record

ArticleCell stem cell2018

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Michael Y Choi, George F Widhopf, Emanuela M Ghia, Reilly L Kidwell, Md Kamrul Hasan, Jian Yu, Laura Z Rassenti, Liguang Chen, Yun Chen, Emily Pittman and 6 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stem cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 129 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02222688 phase1completednot on this map

A Phase I Clinical Trial to Determine the Safety and Tolerability of UC-961 (Cirmtuzumab), an Anti-ROR1 Monoclonal Antibody, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Are Ineligible for Chemotherapy

TypeinterventionalSponsorThomas KippsRan2014 to 2018Enrolled26ConditionsChronic Lymphocytic LeukemiaArmscirmtuzumab
NCT02860676 phase1completednot on this map

A Phase 1 Extension Study to Determine the Safety of UC-961 (Cirmtuzumab) at the Recommended Phase 2 Dose for Retreatment of Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

TypeinterventionalSponsorUniversity of California, San DiegoRan2016 to 2018Enrolled3ConditionsChronic Lymphocytic LeukemiaArmscirmtuzumab
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Beyond the target: implications of Wnt pathway inhibitors on bone health.Journal of molecular medicine (Berlin, Germany) · 2026
    Review
  10. Review
  11. Article
  12. Advancing Immunotherapy in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Michael Y ChoiMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
George F WidhopfMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Emanuela M GhiaMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Reilly L KidwellMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA.
Md Kamrul HasanMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Jian YuMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Laura Z RassentiMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Liguang ChenMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Yun ChenMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Emily PittmanMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA 92093-0901, USA.
Minya PuMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA 92093-0901, USA.
Karen MesserMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA 92093-0901, USA.
Charles E PrussakMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Januario E CastroMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Catriona JamiesonMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92037-0695, USA. Electronic address: cjamieson@ucsd.edu.
Thomas J KippsMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: tkipps@ucsd.edu.
University of California San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
NCI NIH HHS P01 CA081534NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients with chronic lymphocytic leukemia (CLL), self-renewing, neoplastic B cells express ROR1 in 95% of cases. High-level leukemia cell expression of ROR1 is associated with an unfavorable prognosis. We conducted a phase 1 study involving 26 patients with progressive, relapsed, or refractory CLL. Patients received four biweekly infusions, with doses ranging from 0.015 to 20 mg/kg. Cirmtuzumab had a long plasma half-life and did not have dose-limiting toxicity. Inhibition of ROR1 signaling was observed, including decreased activation of RhoA and HS1. Transcriptome analyses showed that therapy inhibited CLL stemness gene expression signatures in vivo. Cirmtuzumab is safe and effective at inhibiting tumor cell ROR1 signaling in patients with CLL.

Indexed as

Antibodies, Monoclonal, HumanizedDose-Response Relationship, DrugDrug ToleranceHumansInfusions, IntravenousLeukemia, Lymphocytic, Chronic, B-CellReceptor Tyrosine Kinase-like Orphan ReceptorsSignal TransductionStructure-Activity RelationshipAntibodies, Monoclonal, HumanizedcirmtuzumabReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, human

Identifiers

PMID29859176
PMCPMC7001723
OpenAlexW2806532541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.